**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 90125

**Manuscript Type:** EDITORIAL

**Metabologenomics and network pharmacology to understand the molecular mechanism of cancer research**

Tutar Y. Metabologenomics

Yusuf Tutar

**Yusuf Tutar,** Department of Basic Pharmaceutical Sciences, Faculty of Pharmacy, Division of Biochemistry, University of Health Sciences, Istanbul 34668, Turkey

**Yusuf Tutar,** Health Sciences Faculty, Recep Tayyip Erdogan University, Rize 53350, Turkey

**Yusuf Tutar,** Molecular Oncology Division, Health Sciences Institutes, University of Health Sciences, Istanbul 34668, Turkey

**Yusuf Tutar,** Molecular Medicine Division, Health Sciences Institutes, University of Health Sciences, Istanbul 34668, Turkey

**Author contributions:** Tutar Y prepared the manuscript.

**Corresponding author: Yusuf Tutar, BSc, MSc, PhD, Academic Editor, Chairman, Dean, Full Professor, Science Editor, Senior Scientist,** Department of Basic Pharmaceutical Sciences, Faculty of Pharmacy, Division of Biochemistry, University of Health Sciences, Mekteb-i Tıbbiye-i Şahane (Hamidiye) Külliyesi Selimiye Mah Tıbbiye Cad, Istanbul 34668, Turkey. ytutar@outlook.com

**Received:** November 23, 2023

**Revised:** December 7, 2023

**Accepted:** December 25, 2023

**Published online:** January 26, 2024

**Abstract**

In this editorial I comment on the article “Network pharmacological and molecular docking study of the effect of Liu-Wei-Bu-Qi capsule on lung cancer” published in the recent issue of the *World Journal of Clinical Cases* 2023 November 6; 11 (31): 7593-7609. Almost all living forms are able to manufacture particular chemicals-metabolites that enable them to differentiate themselves from one another and to overcome the unique obstacles they encounter in their natural habitats. Numerous methods for chemical warfare, communication, nutrition acquisition, and stress prevention are made possible by these specialized metabolites. Metabolomics is a popular technique for collecting direct measurements of metabolic activity from many biological systems. However, confusing metabolite identification is a typical issue, and biochemical interpretation is frequently constrained by imprecise and erroneous genome-based estimates of enzyme activity. Metabolite annotation and gene integration uses a biochemical reaction network to obtain a metabolite-gene association so called metabologenomics. This network uses an approach that emphasizes metabolite-gene consensus *via* biochemical processes. Combining metabolomics and genomics data is beneficial. Furthermore, computer networking proposes that using metabolomics data may improve annotations in sequenced species and provide testable hypotheses for specific biochemical processes.

**Key Words:** Network pharmacology; Metabologenomics; Genome; Pathways; Cancer

**©The** **Author(s) 2024.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Tutar Y. Metabologenomics and network pharmacology to understand the molecular mechanism of cancer research. *World J Clin Cases* 2024; 12(3): 474-478

**URL**: https://www.wjgnet.com/2307-8960/full/v12/i3/474.htm

**DOI**: https://dx.doi.org/10.12998/wjcc.v12.i3.474

**Core Tip:** Regulation of biochemical pathways is similar to Le Chatelier chemical dynamic equilibrium principle. It states that the equilibrium is disrupted by changing the conditions, and the position of dynamic equilibrium shifts to counteract the change to reestablish an equilibrium. Metabolites disrupt pathways either themselves or by enhancing gene expression levels. The equilibrium or “homeostasis” always reestablishes itself to survive the organism. The relationship between genes and metabolites may be discovered by understanding the link through computational networking.

**INTRODUCTION**

Molecules and macromolecules coordinate to regulate metabolism. At cellular level the coordination seems predictable as the hormones and organs do not bring complex interaction. Recent advances in omics technologies have been useful to understand the molecular mechanism of biological processes through distinct algoritms[1].

There are several parameters to be considered when predicting coordination among metabolites, macromolecules, genes and hormones. However, wet lab experiments may not fully compensate the *in silico* experiments since extraction of metabolites with different solutions provides distinct metabolite contents, and organism may transform the molecule to a totally different structure, *i.e.* hydroxylation but the overall information provides general concept of the molecular action. Therefore, databases and software attract scientists to find a relationship between molecules and macromolecules.

**SITES FOR OMICS DATABASES**

Remember that the databases contain more than 220000 metabolites (The Human metabolome database, KEGG, PubChem, MetaCyc, UniProt, and GenBank). Further human genome contains more than 24000 genes (NCBI, EMBL) thus combining metabolite data, genomic data, molecular biology/biochemistry models (molecular docking, simulations, metabolite binding to protein/DNA) and clinical information provides descent information[2]. Linking genomic content to chemical content provides new insights about the pathways involved and crosslink between these pathways. Computational methods provide link to understand correlation of expressed genes and metabolites. Understanding the combinatorial complexity of the biosynthesis of gene clusters and metabolites requires neat strategies to tweak them. *In silico* methods devise strategies to elucidate the essential factors and deciphering metabolite to gene or gene to metabolite approaches and both may provide insights to analyze critical factors on the pathways. It should be noted that none of the methods provide precise results due to limitations of detection methods as well as correlated straight forward mathematical algorithm between metabolites and genes.

**LINKING GENES AND METABOLITES: METABOLOGENOMIC INTEGRATION**

Bioactivity guided fractionation of chemical extracts enabled scientist to elucidate functional metabolites and their corresponding structures. However, lag in acquiring all associated biochemical factors and methodological inadequacies render bioinformatics solutions. Therefore, data mining provides identification of pathways for both known and unknown metabolites[3].

Acquiring metabolic data and assembly technologies of genome sequencing provide the basis of metagenome[4]. Furthermore, recent advances in untargeted metabolomics and analysis of metabolic extracts enabled to determine identity and corresponding gene function. Universally conserved gene and metabolite function helped our understanding of continuity of life and coordinated metabolism through these molecules. One key reason for the coordination of genes and metabolites is genome sequencing and revolutionary assembling/reconstruction of genome from a variety of organisms. These large-scale mining of metabolomes and genomic data not only provided data from distinct organisms but also integrated the metabolites and genes[4]. Computational networking or metabogenomics approaches analyze different organisms and determine common interactions and functions.

Genome mining and metabolome mining may provide details of transcriptional regulation mechanism, although abiotic and biotic environment can be different. However, annotation of metabolites is not an easy task even with tandem mass spectrometers and/or Nuclear Magnetic Resonance spectroscopies (NMRs). Public databases and analysis tools may increase annotation of metabolites, but spectral matching and molecular networking cannot provide structural information. Utilizing *in silico* annotation techniques, fragmentation patterns of a vast array of structures can be computationally learned from known metabolites. These spectra produced *in silico* are then compared to experimental tandem mass spectroscopy data. While this has been successful for certain minor metabolites, it is still too difficult to obtain high-quality annotations by spectral matching for larger natural products[5].

Separation of metabolites by using polar/apolar solvents is another problem as polar solvent extracts polar metabolites or apolar solvents solve apolar metabolites. Also, ionization of the compounds is a must to be detected in mass spectrometry. Thus, some metabolites cannot be detected readily. Although NMR determines these compounds, the technique is not sensitive but the technique is powerful in determining structures of the metabolites.

Despite advances in technology, current analytical platforms cannot measure the whole metabolome entirely. Achieving sufficient metabolome coverage is still a significant problem as mix approaches required. The critical step in metabolomics research is to quench biochemical pathways along with metabolite isolation at a predetermined time to reflect proper metabolite proportion and concentration to mimic original living cell condition. Furthermore, sample collection and extraction must maintain the original metabolite concentration, maximize instrument repeatability, and reduce the matrix influence in the assay.

Metabologenomic integration links datasets and enables structural and functional annotation. Linking the datasets in practice is not an easy task as one needs to integrate multi omics data. Sample handling can be affected by target metabolites and is the source of the most fluctuation. Thus, standardization of these techniques is required for accurate analysis. Mass spectrometry and nuclear magnetic resonance spectroscopy are high-resolution spectroscopic techniques with distinct and interrelated applications in metabolite determination. Each technique may depend on distinct ion sources and prior separation. Standardization is important; however, this is not a demanding but not a feasible process as structures of several metabolites are not commercially available. Furthermore, despite tremendous efforts, the metabolic reprogramming of cancer cells is still not fully understood due to its mechanistic complexity and limitations of current techniques.

**METABOLOGENOMICS AND NETWORK PHARMACOLOGY AT CANCER RESEARCH**

Reports of the metabologenomics and network pharmacology in literature indicate how the approach could be leveraged in the future to improve cancer treatment.

In China, the Xihuang pill is a popular adjuvant medication for cancer patients. One hundred and ninety overlapping candidate targets were used to build the network and enrichment analysis. The target *NR3C2* and its compound naringenin were chosen for additional validation by text mining and molecular docking. A high expression of *NR3C2* was found to support a greater survival probability regarding overall survival, as per the TCGA database. The main active ingredient of Xihuang pill, naringenin, has the ability to reduce the stemness of triple negative breast cancer cells *via* controlling the *NR3C2* gene. This study examined the impact of Xihuang pill on treating advanced triple negative breast cancer cells[6].

Modified nucleosides and ribosylated metabolites in urine samples were the subject of an intriguing metabolomics investigation on breast cancer conducted by Henneges *et al*[6] For this network analysis, a collection of 35 trimmed metabolites was divided into 44 pairwise combinations of metabolite characteristics. Among the metabolite pairs, S-adenosylhomocysteine was the most frequently occurring molecule, indicating its significance for RNA methylation in the pathophysiology of cancer[7].

Untargeted lipidomics was used in a more recent investigation to determine the characteristics that are most crucial for the early identification of lung cancer. Using mass spectrometry, lung plasma lipidomic profiling was performed on 311 individuals. A targeted assay based on mass spectrometry and liquid chromatography was developed using nine lipids. The scientists confirmed the efficacy of these nine lipids in identifying early-stage cancer in many independent cohorts, including a prospective clinical cohort and a hospital-based lung cancer screening cohort[8].

Possible metabolic indicators for oral cavity squamous cell carcinoma were discovered by Hsu *et al*[8] group. The group employed a method to discriminate cancer tissues from nearby non-cancerous tissues precisely by receiver operating characteristic analysis through putrescine, glycyl-leucine, and phenylalanine marker panel[9].

**FUTURE DEVELOPMENTS**

Machine learning techniques are effective solutions to examine metabolomics unstructured data relationships. Metabolomics also complements genomics and transcriptomics. These vast volumes of data form complex network for analysis. Establishing training sets for attribute selection and cross validation provides learning algorithms to get a validated model.

Choosing proper machine learning algorithm is important to determine metabolite-gen link from omics data set. However, machine learning methods have not been developed for reliable outcomes yet. Enrichment studies and pathway analysis define new roles to the identified metabolites. New and larger database, increased computation power, and contemporary machine learning techniques may provide precise diagnosis and treatment[10].

**CONCLUSION**

The genome and metabolites of biological organisms are not fully characterized with current technologies. However, increasing high-throughput metabolomics and genomics data provide promising generation of paired data sets to understand the molecular mechanism of biochemical processes as well as determining targets for pharmaceutical drug design. Contemporary network infrastructures to integrate omics analysis can provide molecular mechanism of biochemical pathways. Furthermore, clinical data may be integrated to gene expression – metabolite expression by system genetics approach. Calculating pair-wise correlations and weighted correlation network analysis provide the basis of this integration[11-13]. The occurrence of strong correlations between classified metabolites and co-expression transcripts implies either various roles of metabolites or linkages between metabolic pathways and the immune system.

**REFERENCES**

1 **Ergul M**, Aktan F, Yildiz MT, Tutar Y. Perturbation of HSP Network in MCF-7 Breast Cancer Cell Line Triggers Inducible HSP70 Expression and Leads to Tumor Suppression. *Anticancer Agents Med Chem* 2020; **20**: 1051-1060 [PMID: 32053081 DOI: 10.2174/1871520620666200213102210]

2 **Danzi F**, Pacchiana R, Mafficini A, Scupoli MT, Scarpa A, Donadelli M, Fiore A. To metabolomics and beyond: a technological portfolio to investigate cancer metabolism. *Signal Transduct Target Ther* 2023; **8**: 137 [PMID: 36949046 DOI: 10.1038/s41392-023-01380-0]

3 **Medema MH**, Fischbach MA. Computational approaches to natural product discovery. *Nat Chem Biol* 2015; **11**: 639-648 [PMID: 26284671 DOI: 10.1038/nchembio.1884]

4 **Navarro-Muñoz JC**, Selem-Mojica N, Mullowney MW, Kautsar SA, Tryon JH, Parkinson EI, De Los Santos ELC, Yeong M, Cruz-Morales P, Abubucker S, Roeters A, Lokhorst W, Fernandez-Guerra A, Cappelini LTD, Goering AW, Thomson RJ, Metcalf WW, Kelleher NL, Barona-Gomez F, Medema MH. A computational framework to explore large-scale biosynthetic diversity. *Nat Chem Biol* 2020; **16**: 60-68 [PMID: 31768033 DOI: 10.1038/s41589-019-0400-9]

5 **Zhang YZ**, Yang JY, Wu RX, Fang C, Lu H, Li HC, Li DM, Zuo HL, Ren LP, Liu XY, Xu R, Wen JH, Huang HD, Hong R, Chen QJ. Network Pharmacology-Based Identification of Key Mechanisms of Xihuang Pill in the Treatment of Triple-Negative Breast Cancer Stem Cells. *Front Pharmacol* 2021; **12**: 714628 [PMID: 34737698 DOI: 10.3389/fphar.2021.714628]

6 **Henneges C**, Bullinger D, Fux R, Friese N, Seeger H, Neubauer H, Laufer S, Gleiter CH, Schwab M, Zell A, Kammerer B. Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection. *BMC Cancer* 2009; **9**: 104 [PMID: 19344524 DOI: 10.1186/1471-2407-9-104]

7 **Wang G**, Qiu M, Xing X, Zhou J, Yao H, Li M, Yin R, Hou Y, Li Y, Pan S, Huang Y, Yang F, Bai F, Nie H, Di S, Guo L, Meng Z, Wang J, Yin Y. Lung cancer scRNA-seq and lipidomics reveal aberrant lipid metabolism for early-stage diagnosis. *Sci Transl Med* 2022; **14**: eabk2756 [PMID: 35108060 DOI: 10.1126/scitranslmed.abk2756]

8 **Hsu CW**, Chen YT, Hsieh YJ, Chang KP, Hsueh PC, Chen TW, Yu JS, Chang YS, Li L, Wu CC. Integrated analyses utilizing metabolomics and transcriptomics reveal perturbation of the polyamine pathway in oral cavity squamous cell carcinoma. *Anal Chim Acta* 2019; **1050**: 113-122 [PMID: 30661578 DOI: 10.1016/j.aca.2018.10.070]

9 **van der Hooft JJJ**, Mohimani H, Bauermeister A, Dorrestein PC, Duncan KR, Medema MH. Linking genomics and metabolomics to chart specialized metabolic diversity. *Chem Soc Rev* 2020; **49**: 3297-3314 [PMID: 32393943 DOI: 10.1039/d0cs00162g]

10 **Galal A**, Talal M, Moustafa A. Applications of machine learning in metabolomics: Disease modeling and classification. *Front Genet* 2022; **13**: 1017340 [PMID: 36506316 DOI: 10.3389/fgene.2022.1017340]

11 **Ponsuksili S**, Trakooljul N, Hadlich F, Methling K, Lalk M, Murani E, Wimmers K. Genetic Regulation of Liver Metabolites and Transcripts Linking to Biochemical-Clinical Parameters. *Front Genet* 2019; **10**: 348 [PMID: 31057604 DOI: 10.3389/fgene.2019.00348]

12 **Rueedi R**, Ledda M, Nicholls AW, Salek RM, Marques-Vidal P, Morya E, Sameshima K, Montoliu I, Da Silva L, Collino S, Martin FP, Rezzi S, Steinbeck C, Waterworth DM, Waeber G, Vollenweider P, Beckmann JS, Le Coutre J, Mooser V, Bergmann S, Genick UK, Kutalik Z. Genome-wide association study of metabolic traits reveals novel gene-metabolite-disease links. *PLoS Genet* 2014; **10**: e1004132 [PMID: 24586186 DOI: 10.1371/journal.pgen.1004132]

13 **Yang Q**, Li LY. Network pharmacological and molecular docking study of the effect of Liu-Wei-Bu-Qi capsule on lung cancer. *World J Clin Cases* 2023; **11**: 7593-7609 [PMID: 38078145 DOI: 10.12998/wjcc.v11.i31.7593]

**Footnotes**

**Conflict-of-interest statement:** The author reports no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** World Academy of Sciences; Turkish National Academy of Sciences-Young Scientist; The Scientific Research Honor Society; Asian Council of Science Editors; World Association of Medical Editors; Teaching Academy Fellow, Texas Tech University; Honor Society Membership, Texas Tech University.

**Peer-review started:** November 23, 2023

**First decision:** November 28, 2023

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** Turkey

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Ma MZ, China **S-Editor:** Li L **L-Editor:** A **P-Editor:** Li L



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** office@baishideng.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2024 Baishideng Publishing Group Inc. All rights reserved.**